Novacyt S.A.: Launch of Three Innovative Products to Support COVID-19 Testing
18 Junho 2020 - 3:00AM
Business Wire
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the
"Company" or the “Group”), an international specialist in clinical
diagnostics, announces the launch of three new products to support
laboratories testing for COVID-19. These are Exsig™ Direct and
Exsig™ Mag, two RNA extraction kits for use prior to running a
polymerase chain reaction (PCR) test for COVID-19, and COVID-HT, a
high-throughput test for COVID-19.
Exsig™ Direct and Exsig™ Mag In addition to supporting
laboratories through the supply of its COVID-19 test, Novacyt has
developed two RNA extraction kits, Exsig™ Direct and Exsig™ Mag, to
help address the current reported global shortfall in extraction
reagents required to perform PCR testing. The extraction of RNA is
a key pre-analytical step in COVID-19 testing and must be performed
before running the PCR test on the RNA extract. The two kits can be
used with all open instrument platforms for running a PCR test and
offer customers different benefits; Exsig™ Direct provides
significant workflow improvements whilst Exsig™ Mag offers enhanced
sensitivity of the Company’s COVID-19 test.
Exsig™ Direct is an innovative direct-to-PCR extraction kit
which removes the need for complex, automated magnetic bead
extraction systems. It is designed to be used with the Company’s
COVID-19 test and is expected to significantly improve laboratory
workflow, reduce cycle times, increase throughput by up to 50% and
reduce costs. It uses a combination of optimised buffers to extract
COVID-19 RNA from clinical samples. These buffers have been
specifically designed and clinically tested to ensure the high
level of testing performance of the Company’s COVID-19 test is
maintained. Novacyt also plans to optimise the use of this new
extraction method in future PCR tests to be developed and launched
by the Company.
Exsig™ Mag is a new extraction kit designed to run on multiple
automated magnetic bead extraction systems commonly used by
clinical laboratories around the world. Exsig™ Mag has been
developed to enhance extraction of COVID-19 RNA from clinical
samples and, when used in combination with the Company’s COVID-19
test, offers ultra-sensitive detection of COVID-19. Exsig™ Mag can
also be used in combination with other COVID-19 PCR tests.
COVID-HT test COVID-HT is a new test for COVID-19
optimised for use in laboratories performing high volumes of tests.
The CE Mark test has been designed and validated to perform at the
same high levels of specificity and sensitivity as the Company’s
existing COVID-19 test.
COVID-HT uses the Company’s proprietary master mix which, unlike
the standard COVID-19 kit, requires no premixing, and the test
components are packaged to facilitate a more streamlined workflow
in a highly automated laboratory setting. As a result, COVID-HT is
expected to improve operational efficiency and save time and labour
associated with handling and preparing the test for use.
Exsig™ Direct, Exsig™ Mag and COVID-HT are immediately available
and manufacturing capacity has been developed to meet potential
demand.
Graham Mullis, Group CEO of Novacyt, commented: “As we
continue to supply our COVID-19 test to laboratories around the
world, we are delighted to provide further support through the
launch of these new products. We believe there will be significant
demand for our new extraction kits, particularly at this time when
automated RNA extraction reagents are in short supply. In addition,
our high-throughput test, for use in large volume clinical
laboratories, should enable more efficient workflow which is
critical to achieve optimal testing volumes. We look forward to
continuing to work with our customers to support their testing
requirements through new and innovative solutions.”
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
About Novacyt Group The Novacyt Group is an
international diagnostics business generating an increasing
portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development,
commercialisation, contract design and manufacturing. The Company's
lead business units comprise of Primerdesign and Lab21 Products,
supplying an extensive range of high-quality assays and reagents
worldwide. The Group directly serves microbiology, haematology and
serology markets as do its global partners, which include major
corporates.
For more information please refer to the website:
www.novacyt.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200617005884/en/
Novacyt SA Graham Mullis, Chief Executive Officer Anthony
Dyer, Chief Financial Officer +44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470
0470
FTI Consulting (International) Victoria Foster Mitchell /
Mary Whittow +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France) Arnaud de Cheffontaines +33
(0)147 03 69 47 arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024